Fenwick & West represented OrsoBio in the transaction.OrsoBio,Inc. a clinical-stage biopharmaceutical company developing treatments for obesity and obesity-associated disorders, announced raising its $67 million Series B…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
